Docoh
Loading...

LXRX Lexicon Pharmaceuticals

Filed: 3 May 21, 4:08pm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________

FORM 8-K
__________________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 29, 2021

Lexicon Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware000-3011176-0474169
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)(I.R.S. Employer
Identification Number)

8800 Technology Forest Place
The Woodlands, Texas 77381
(Address of principal executive offices and Zip Code)

(281) 863-3000
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001LXRXThe Nasdaq Global Select Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.






Item 1.01     Entry into a Material Definitive Agreement

On April 29, 2021, our stockholders approved an amendment to our 2017 Non-Employee Directors’ Equity Incentive Plan increasing the total number of shares of our common stock that may be issued pursuant to stock awards granted under the plan from 600,000 to 1,200,000.
The foregoing summary does not purport to be complete and is qualified in its entirety by our 2017 Non-Employee Directors’ Equity Incentive Plan, as amended, a copy of which is attached to this report as Exhibit 10.1 and incorporated herein by reference.


Item 3.03    Material Modification to Rights of Security Holders

To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this report is incorporated herein by reference.


Item 5.03    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On April 30, 2021, we filed a Second Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware, which became effective on the filing date. The Second Amended and Restated Certificate of Incorporation grants holders of 20% or more of our issued and outstanding common stock (a) customary preemptive rights and (b) consent rights prior to us taking any of the following actions: (i) creating or issuing any new class or series of shares of capital stock (or securities convertible into or exercisable for shares of capital stock) having rights, preferences or privileges senior to or on parity with the common stock, (ii) subject to certain customary exceptions, repurchasing, retiring, redeeming or otherwise acquiring any of our equity securities (or securities convertible into or exchangeable for our equity securities) and (iii) adopting, or proposing to adopt, or maintaining any shareholders’ rights plan, “poison pill” or other similar plan or agreement, unless such stockholder is exempt from the provisions of such shareholders’ rights plan, “poison pill” or other similar plan or agreement.

The foregoing summary does not purport to be complete and is qualified in its entirety by our Second Amended and Restated Certificate of Incorporation, a copy of which is attached to this report as Exhibit 3.1 and incorporated herein by reference.


Item 5.07    Submission of Matters to a Vote of Security Holders

Our annual meeting of stockholders was held on April 29, 2021 to consider and vote on the following proposals. The voting results with respect to each matter are set forth below:



(1)Election of Class III Directors
Name of DirectorForWithheld
Broker
Non-Votes
Philippe J. Amouyal104,066,2899,551,12111,677,330
Lonnel Coats113,017,046600,36411,677,330
Frank P. Palantoni108,872,1134,745,29711,677,330
ForAgainstWithheld
Broker
Non-Votes
(2)Ratification and approval of the Company's Second Amended and Restated Certificate of Incorporation92,542,67220,518,676556,06211,677,330
ForAgainstWithheld
Broker
Non-Votes
(3)Ratification and approval of the amendment to the Company's 2017 Non-Employee Directors’ Equity Incentive Plan111,261,1302,288,48367,79711,677,330
ForAgainstWithheld
Broker
Non-Votes
(4)Advisory vote to approve the compensation paid to the Company's named executive officers94,641,71718,373,001602,69211,677,330
ForAgainstWithheld
Broker
Non-Votes
(5)Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2021125,012,456116,013166,271

Item 9.01    Financial Statements and Exhibits

(d)    Exhibits



Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Lexicon Pharmaceuticals, Inc.
Date: May 3, 2021By:/s/ Brian T. Crum
Brian T. Crum
Vice President and General Counsel